Ann: Dimerix to present at Melbourne Twilight Investor Briefing, page-11

Yeah good but nothing special imo.

(i was just googling AA again and reading up on drugs that arent as good as existing drugs, can still get AA). The fda simply need to see its giving statistical benefit.

the interim analysis is a massive derisk. Unless the drugs efficacy squiggles like a charted wave - up n down - v unlikely, we alreadyhave a minimum 35% efficacy result, MINIMUM.

Correct me please if others think diff, but is this for real? Nina said as quoted above that;
% change of interim = same or better than ph2
% change is the fda approved endpoint